Yu-Shan Teng
Research Subjects
Yu-Shan Teng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chih-Hsin Lin
Department of Neurology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taoyuan 33302, Taiwan
1 shared publication - Chiung-Mei Chen
Department of Neurology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, 33378, Taiwan
1 shared publication - Chung-Yin Lin
Medical Imaging Research Center, Institute for Radiological Research, Chang Gung University/Chang Gung Memorial Hospital, Taoyuan, Taiwan
1 shared publication - Guey-Jen Lee-Chen
School of Life Science, National Taiwan Normal University, Taipei, 11677, Taiwan
1 shared publication - Hsiu Mei Hsieh-Li
Department of Life Science, National Taiwan Normal University, Taipei, Taiwan
1 shared publication - Kuo-Hsuan Chang
Department of Neurology, Chang Gung Memorial Hospital and University School of Medicine, Taoyuan, Taiwan
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Novel Synthetic Coumarin‐Chalcone Derivative (E)‐3‐(3‐(4‐(Dimethylamino)Phenyl)Acryloyl)‐4‐Hydroxy‐2H‐Chromen‐2‐One Activates CREB‐Mediated Neuroprotection in Aβ and Tau Cell Models of Alzheimer’s Disease
Abnormal accumulations of misfolded Aβ and tau proteins are major components of the hallmark plaques and neurofibrillary tangles in the brains of Alzheimer’s disease (AD) patients. These abnormal protein deposits cause neurodegeneration through a number of proposed mechanisms, including downregulation of the cAMP‐response‐element (CRE) binding protein 1 (CREB) signaling pathway. Using CRE‐GFP reporter cells, we investigated the effects of three coumarin‐chalcone derivatives synthesized in our lab on CREB‐mediated gene expression. Aβ‐GFP‐ and ΔK280 tauRD‐DsRed‐expressing SH‐SY5Y cells were used to evaluate these agents for possible antiaggregative, antioxidative, and neuroprotective effects. Blood‐brain barrier (BBB) penetration was assessed by pharmacokinetic studies in mice. Of the three tested compounds, (E)‐3‐(3‐(4‐(dimethylamino)phenyl)acryloyl)‐4‐hydroxy‐2H‐chromen‐2‐one (LM‐021) was observed to increase CREB‐mediated gene expression through protein kinase A (PKA), Ca2+/calmodulin‐dependent protein kinase II (CaMKII), and extracellular signal‐regulated kinase (ERK) in CRE‐GFP reporter cells. LM‐021 exhibited antiaggregative, antioxidative, and neuroprotective effects mediated by the upregulation of CREB phosphorylation and its downstream brain‐derived neurotrophic factor and BCL2 apoptosis regulator genes in Aβ‐GFP‐ and ΔK280 tauRD‐DsRed‐expressing SH‐SY5Y cells. Blockage of the PKA, CaMKII, or ERK pathway counteracted the beneficial effects of LM‐021. LM‐021 also exhibited good BBB penetration ability, with brain to plasma ratio of 5.3%, in in vivo pharmacokinetic assessment. Our results indicate that LM‐021 works as a CREB enhancer to reduce Aβ and tau aggregation and provide neuroprotection. These findings suggest the therapeutic potential of LM‐021 in treating AD.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessNovel Synthetic Coumarin‐Chalcone Derivative (E)‐3‐(3‐(4‐(Dimethylamino)Phenyl)Acryloyl)‐4‐Hydroxy‐2H‐Chromen‐2‐One Activates CREB‐Mediated Neuroprotection in Aβ and Tau Cell Models of Alzheimer’s Disease
Abnormal accumulations of misfolded Aβ and tau proteins are major components of the hallmark plaques and neurofibrillary tangles in the brains of Alzheimer’s disease (AD) patients. These abnormal protein deposits cause neurodegeneration through a number of proposed mechanisms, including downregulation of the cAMP‐response‐element (CRE) binding protein 1 (CREB) signaling pathway. Using CRE‐GFP reporter cells, we investigated the effects of three coumarin‐chalcone derivatives synthesized in our lab on CREB‐mediated gene expression. Aβ‐GFP‐ and ΔK280 tauRD‐DsRed‐expressing SH‐SY5Y cells were used to evaluate these agents for possible antiaggregative, antioxidative, and neuroprotective effects. Blood‐brain barrier (BBB) penetration was assessed by pharmacokinetic studies in mice. Of the three tested compounds, (E)‐3‐(3‐(4‐(dimethylamino)phenyl)acryloyl)‐4‐hydroxy‐2H‐chromen‐2‐one (LM‐021) was observed to increase CREB‐mediated gene expression through protein kinase A (PKA), Ca2+/calmodulin‐dependent protein kinase II (CaMKII), and extracellular signal‐regulated kinase (ERK) in CRE‐GFP reporter cells. LM‐021 exhibited antiaggregative, antioxidative, and neuroprotective effects mediated by the upregulation of CREB phosphorylation and its downstream brain‐derived neurotrophic factor and BCL2 apoptosis regulator genes in Aβ‐GFP‐ and ΔK280 tauRD‐DsRed‐expressing SH‐SY5Y cells. Blockage of the PKA, CaMKII, or ERK pathway counteracted the beneficial effects of LM‐021. LM‐021 also exhibited good BBB penetration ability, with brain to plasma ratio of 5.3%, in in vivo pharmacokinetic assessment. Our results indicate that LM‐021 works as a CREB enhancer to reduce Aβ and tau aggregation and provide neuroprotection. These findings suggest the therapeutic potential of LM‐021 in treating AD.